Race Oncology Investor Presentation - November 2021
Filed with ASX · · 43 pages · English
Investment in Race Oncology (Race) is subject to investment risk, including possible loss of income and capital invested. Race does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take into account the investment
Earlier from Racura Oncology
- Race Oncology Share Purchase Plan
- AGM Presentations
- Breakthrough Zantrene Heart Protection Discovery
- University of Wollongong R&D Collaboration
- Race secures sixth US patent for Zantrene
Later from Racura Oncology
- Race Oncology: Notification regarding unquoted securities - RAC
- Expanded Heart Protection Discovery for Zantrene
- Race raises $29.7 million in oversubscribed SPP
- MD Anderson Preclinical AML Study on Zantrene Published
- Race Oncology: Application for quotation of securities - RAC
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology